首页> 外文期刊>The Journal of Physiology >Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome.
【24h】

Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome.

机译:氟卡尼和奎尼丁对模拟Brugada综合征的Scn5a +/-小鼠心脏的心律失常特性的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Brugada syndrome (BrS) is associated with a loss of Na+ channel function and an increased incidence of rapid polymorphic ventricular tachycardia (VT) and sudden cardiac death. A programmed electrical stimulation (PES) technique assessed arrhythmic tendency in Langendorff-perfused wild-type (WT) and genetically modified (Scn5a+/-) 'loss-of-function' murine hearts in the presence and absence of flecainide and quinidine, and the extent to which Scn5a+/- hearts model the human BrS. Extra-stimuli (S2), applied to the right ventricular epicardium, followed trains of pacing stimuli (S1) at progressively reduced S1-S2 intervals. These triggered VT in 16 out of 29 untreated Scn5a+/- and zero out of 31 WT hearts. VT occurred in 11 out of 16 (10 microM) flecainide-treated WT and nine out of the 13 initially non-arrhythmogenic Scn5a+/- hearts treated with (1.0 microM) flecainide. Quinidine (10 microM) prevented VT in six out of six flecainide-treated WT and 13 out of the 16 arrhythmogenic Scn5a+/- hearts in parallel with its clinical effects. Paced electrogram fractionation analysis demonstrated increased electrogram durations, expressed as electrogram duration (EGD) ratios, with shortening S1-S2 intervals in arrhythmogenic Scn5a+/- hearts, and prolonged ventricular effective refractory periods (VERPs) in non-arrhythmogenic Scn5a+/- hearts. Flecainide increased EGD ratios in WT (at 10 microM) and non-arrhythmogenic Scn5a+/- hearts (at 1.0 microM), whereas quinidine (10 microM) reduced EGD ratios and prolonged VERPs in WT and arrhythmogenic Scn5a+/- hearts. However, epicardial and endocardial monophasic action potential recordings consistently demonstrated positive gradients of repolarization in WT, arrhythmogenic and non-arrhythmogenic Scn5a+/- hearts under all pharmacological conditions. Together, these findings demonstrate proarrhythmic effects of flecainide in WT and Scn5a+/- murine hearts that recapitulate its clinical effects. They further attribute the arrhythmogenic phenomena observed here to re-entrant substrates resulting from delayed epicardial activation despite an absence of transmural heterogeneities of repolarization, in sharp contrast to recent characterizations in 'gain-of-function' Scn5a+/Delta murine hearts modelling the long-QT(3) syndrome.
机译:Brugada综合征(BrS)与Na +通道功能丧失,快速多形性室性心动过速(VT)和心源性猝死的发生率增加有关。程序电刺激(PES)技术评估了在存在和不存在flecainide和quinidine的情况下,Langendorff灌注的野生型(WT)和基因修饰的(Scn5a +/-)'功能丧失'小鼠心脏的心律失常趋势。 Scn5a +/-心脏对人类BrS建模的程度。施加于右心室心外膜的额外刺激(S2),以逐渐减小的S1-S2间隔跟随一系列起搏刺激(S1)。这些触发了29例未经治疗的Scn5a +/-中的16例中的VT,而31例WT心脏中的0了。在16例(10 microM)氟卡尼治疗的WT中,有11例发生了VT,在最初用(1.0 microM)氟卡尼治疗的非致心律失常的Scn5a +/-心脏中,有9例发生了VT。奎尼丁(10 microM)预防了6例氟卡尼治疗的WT患者中的6例以及16例致心律失常的Scn5a +/-心脏中的13例患者发生了VT,同时具有临床效果。起搏电描记分析表明,增加的电描记持续时间(以电描记持续时间(EGD)比表示),缩短了致心律不齐的Scn5a +/-心脏中的S1-S2间隔,并延长了非心律失常的Scn5a +/-心脏中的心室有效不应期(VERP)。 Flecainide增加了WT(10 microM)和非心律失常性Scn5a +/-心脏中的EGD比率(1.0 microM),而奎尼丁(10 microM)降低了WT和不致心律失常性Scn5a +/-心脏中的EGD比率并延长了VERPs。然而,心外膜和心内膜单相动作电位记录一致地表明,在所有药理条件下,WT,心律失常和非心律失常的Scn5a +/-心脏的复极化呈正梯度。总之,这些发现证明了氟卡尼在野生型和Scn5a +/-小鼠心脏中的心律失常作用,可概括其临床效果。他们进一步将此处观察到的导致心律失常的现象归因于心外膜激活延迟而导致的折返基质,尽管没有透极化的透壁异质性,这与最近对“获得功能的” Scn5a + / Delta鼠心脏进行建模的特征形成鲜明对比。 QT(3)综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号